Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $138.9 million.

  • Monte Rosa Therapeutics' Net Cash Flow rose 72834.82% to $138.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 2377.07%. This contributed to the annual value of $96.4 million for FY2024, which is 3303.17% up from last year.
  • Monte Rosa Therapeutics' Net Cash Flow amounted to $138.9 million in Q3 2025, which was up 72834.82% from -$9.0 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Net Cash Flow registered a high of $138.9 million during Q3 2025, and its lowest value of -$145.7 million during Q1 2025.
  • In the last 3 years, Monte Rosa Therapeutics' Net Cash Flow had a median value of $9.1 million in 2024 and averaged $13.9 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 81659.05% in 2024, then soared by 72834.82% in 2025.
  • Monte Rosa Therapeutics' Net Cash Flow (Quarter) stood at $69.1 million in 2023, then surged by 42.73% to $98.6 million in 2024, then surged by 40.84% to $138.9 million in 2025.
  • Its Net Cash Flow stands at $138.9 million for Q3 2025, versus -$9.0 million for Q2 2025 and -$145.7 million for Q1 2025.